Cargando…

Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1

Transporters are important therapeutic but yet understudied targets due to lack of available assays. Here we describe a novel label-free, whole-cell method for the functional assessment of Solute Carrier (SLC) inhibitors. As many SLC substrates are also ligands for G protein-coupled receptors (GPCRs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlachodimou, Anna, IJzerman, Adriaan P., Heitman, Laura H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760145/ https://www.ncbi.nlm.nih.gov/pubmed/31551431 http://dx.doi.org/10.1038/s41598-019-48829-3

Ejemplares similares

Functional characterization of human equilibrative nucleoside transporter 1
por: Huang, Weiyun, et al.
Publicado: (2016)

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease
por: Guitart, Xavier, et al.
Publicado: (2017)

HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
por: Eltzschig, Holger K., et al.
Publicado: (2005)

Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.
por: Pressacco, J., et al.
Publicado: (1995)

Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles
por: Naes, Safaa M., et al.
Publicado: (2020)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29)
por: Pastor-Anglada, Marçal, et al.
Publicado: (2022)

Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters
por: Miller, Siennah R., et al.
Publicado: (2021)

Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1)
por: Boswell-Casteel, Rebba C., et al.
Publicado: (2018)

FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia
por: Català, Albert, et al.
Publicado: (2016)

Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors
por: Sijben, Hubert J., et al.
Publicado: (2021)

Novel variants provide differential stabilisation of human equilibrative nucleoside transporter 1 states
por: Boakes, Jessica C., et al.
Publicado: (2022)

Identification of Structural and Molecular Features Involved in the Transport of 3′-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3
por: Rahman, MD Fazlur, et al.
Publicado: (2018)

Equilibrative nucleoside transporter 1 (ENT1) is critical for pollen germination and vegetative growth in Arabidopsis
por: Bernard, Carsten, et al.
Publicado: (2011)

Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice
por: Best, K. Arielle, et al.
Publicado: (2018)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside Transporters
por: Aseervatham, Jaya, et al.
Publicado: (2015)

Mutations in SLC29A3, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease
por: Morgan, Neil V., et al.
Publicado: (2010)

Sustained adenosine exposure causes endothelial mitochondrial dysfunction via equilibrative nucleoside transporters
por: Ko, Junsuk, et al.
Publicado: (2020)

Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes
por: Perrone, G., et al.
Publicado: (2010)

Equilibrative Nucleoside Transporters-1 Inhibitors Act as Anti-epileptic Agents by Inhibiting Glutamatergic Transmission
por: Ho, Shih-Yin, et al.
Publicado: (2020)

Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy
por: Chang, Ching-Pang, et al.
Publicado: (2021)

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development
por: Deniskin, Roman, et al.
Publicado: (2015)

N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function
por: Bicket, Alex, et al.
Publicado: (2016)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
por: Hubeek, I, et al.
Publicado: (2005)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Adenosine Suppresses Cholangiocarcinoma Cell Growth and Invasion in Equilibrative Nucleoside Transporters-Dependent Pathway
por: Lertsuwan, Kornkamon, et al.
Publicado: (2020)

MPP(+)-Induced Changes in Cellular Impedance as a Measure for Organic Cation Transporter (SLC22A1-3) Activity and Inhibition
por: Mocking, Tamara A. M., et al.
Publicado: (2022)

Export of RNA-derived modified nucleosides by equilibrative nucleoside transporters defines the magnitude of autophagy response and Zika virus replication
por: Shi, Sheng-Lan, et al.
Publicado: (2021)

Dynamic-related protein 1 inhibitor eases epileptic seizures and can regulate equilibrative nucleoside transporter 1 expression
por: Luo, Zhong, et al.
Publicado: (2020)

Type 1 equilibrative nucleoside transporter regulates astrocyte-specific glial fibrillary acidic protein expression in the striatum
por: Hinton, David J, et al.
Publicado: (2014)

Equilibrative Nucleoside Transporters Mediate the Import of Nicotinamide Riboside and Nicotinic Acid Riboside into Human Cells
por: Kropotov, Andrey, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter‐1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S‐1 chemotherapy
por: Okamura, Yukiyasu, et al.
Publicado: (2019)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia–Reperfusion Injury?
por: Yang, Cui, et al.
Publicado: (2015)

Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
por: Attia, Fadia, et al.
Publicado: (2020)

Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
por: Ruan, Wei, et al.
Publicado: (2023)

Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
por: Logie, Lisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qo4jin12h5kej4p6as4npil9o8